@

Meet us

NextMeeting

Supporting the fight against COVID-19

Learn how Sciomics supports COVID-19 research

 

Accelerated research is the best opportunity to increase the understanding of COVID-19 disease and efficiently fighting the novel coronavirus SARS-CoV-2. Testing multiple proteins in parallel accelerates your research and enables in-depth insights regarding the underlying molecular mechanisms.

 

Learn here how multiplex protein profiling can support your COVID-19 research. All information is also available as a pdf.

 

 

   Immune Response Profiling & Biomarker Discovery

> Immune Response Profiling

Explore how the immune system reacts to a SARS-CoV-2 infection in different age groups, risk groups and certain individuals. Are there common mechanisms which can be used for preventing severe disease ?  A parallel profiling of 121 cytokines / chemokines and 141 cell surface markers can provide novel insights. Such analyses are possible from patient samples (plasma / serum), cell culture as well as animal models.

> Disease Severity biomarkers for COVID-19

Discover new biomarkers for COVID-19 patient stratification, early prevention and improvement of disease management by multiplex screens from plasma or serum samples.
< scioDiscover >

> Outcome Prediction after positive SARS-CoV-2 test

Identify risk factors and correlating protein biomarkers indicating severe COVID-19 progression for improved disease management.
< scioDiscover >

 

    Development of therapeutics against COVID-19

> Benchmarking of Therapeutics & Drug Repurposing

Accelerate your COVID-19 research by assessing pathway activity, early toxicology and mechanisms of action for an efficient benchmarking of compounds or drug repurposing candidates.
< scioDiscover >  < scioPhospho >

> Therapy Response biomarkers

Identify predictive biomarkers for your COVID-19 drug candidate to stratify responders from non-responders
< scioDiscover >

 

   Development of vaccines against SARS-CoV-2

> SARS-CoV-2 vaccine development

In-depth analysis of responses to vaccine candidates from animal and patient samples. Analyses are possible from plasma / serum samples or from purified immune cells.
< scioCD >  < scioDiscover >  < scioPhospho >

> Profiling of animal models

Characterize response in different model organisms (mouse, rat and more) for your SARS-CoV-2 vaccine development
< scioDiscover >  < scioPhospho >

> Screening of viral SARS-CoV-2 epitopes

Analyse the antibody response to different vaccine candidates in animal models and patients using plasma/serum samples.
Analyse serum samples from COVID-19 patients to identify highly immunogenic epitopes.

 

   Assays available

scioCD - 121 cytokines and 141 CD cell surface markers for immune profiling

Parallel profiling of 121 cytokines / chemokines and 141 CD cell surface markers from plasma/serum, immune cells or tissue samples.

scioDiscover - screening of 1,300 proteins in parallel

The protein panel for biomarker discovery on plasma/serum, cell or tissue samples include

  • inflammatory mediators
  • immune checkpoint molecules
  • immune cells markers
  • soluble proteins
  • membrane/receptor proteins
  • intracellular proteins

< more information >

scioPhospho - combined phosphorylation and expression profiling of 1,300 proteins

Combine a scioDiscover screen with information on phosphorylation status for all 1,300 proteins in one assay. Typical applications are mode-of-action studies, pathway activity profiling or mechanistic understanding of disease as well as therapeutic response.
< more information >


Common assay specifications

  • Minimal sample amount required (20 µL plasma/serum, 500,000 cells, 10mg of tissue)
  • Complete analysis service from sample to study report
  • All assays can be complemented by a SARS-CoV-2 proteome wide peptide array < more information >

 

   Get in touch with our scientific team

Phone + 49 (0) 6221 4294830                                                                
This email address is being protected from spambots. You need JavaScript enabled to view it.
covid 19 immuneResponse v2 web

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status
scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level
Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling
  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi
Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioCyto : Cytokine profiling

scioCyto : Cytokine profiling
scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Prevention of Cyclosp.-A mediated anemia and peritubular loss

| June 2022 | In a study by Robert Labes et al. insights in prevention of cyclosporine mediated anemia and peritubular capillary loss were identified.

Labes, R. et al. Daprodust. prevents cyclosp.-A mediated anemia and peritubular capillary loss. Kidney International 2022 in press.
New article | The Lifestyle Modifications Affect the Endometrial Proteome

| June 2022 | In a study by D. Abdulkhalikova et al. Endometrial Proteome changes werde identified impacted by Lifestyle modification in woman with Polycystic Ovarian Syndrome and Obesity.

Abdulkhalikova, DR. et al. The Lifestyle Modifications and Endometrial Proteome Changes of Women With Polycystic Ovary Syndrome and Obesity. Front. Endocrinol. 2022 in press.
New article | Cycle-dependent biomarkers in endometriosis

| May 2022 | In a study by Maja Pušić et al. Cycle-dependent plasma protein biomarkers for peritoneal endometriosis were identified by our scioDiscover platform.

Pušić, M. et al. Antibody Arrays Identified Cycle-Dependent Plasma Biomarker Candidates of Peritoneal Endometriosis. J. Pers. Med. 2022, 12, 852.
New article | Co-Expression of microRNAs and Proteins in Alzheimer’s Disease

| Jan 2022 | In a study by Valentina di Pietro at Birmingham University our scioDoiscover platform was used to analyse the co-expression of proteins and microRNAs in the brains of Alzheimer's disease patients.

Watson, C. N. et al. Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients. Cells 11, 163 (2022).
New article | ETV6 levels predict outcome in DLBCL

| Jan 2022 | Erich Piovan and collegues at University of Padua collaborated with Sciomics to study specific biomarkers in FFPE tissue samples of DLBCL patients by custom antibody microarrays.

Marino, D. et al. High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. Cancers 14, (2022).

Testimonials

Dr. Bettina Grötsch

Department of Medicine 3 - Rheumatology and Immunology, University Clinics Erlangen, Erlangen, Germany

"Our lab is working with human osteoclast that were isolated and differentiated from human peripheral blood. Therefore, we were quite limited in cell numbers and protein content for our planned Phosphoprotein analyses. Nonetheless, Sciomics and especially Camille Lowy helped us a lot to test and improve our protein isolation techniques to achieve some interesting phosphoproteome data in human osteoclasts. We were really impressed by the detailed data report and their willingness to discuss and reanalyze the data repeatedly until we got the best results out of our measurements. Even several month after their first report, we could ask for help and suggestions with an immediate reply.  The phosphoproteome analyses completed our preliminary project data and are now published in Frontiers Immunology.  Altogether, we were very happy with the service of Sciomics and special thanks to Camille Lowy and Christoph Schröder who guided us through the whole process."

Product: scioPhospho
Publication: Grötsch B. et al. 2022 Front. Immunol. 13:958974 

Alenka Djarmila Behsen, PhD candidate

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

"The process of working with Ronny and his colleagues at Sciomics has been very easy and efficient. Response time is very quick and they are always available for meetings when you have more questions. Would definitely recommend working with Sciomics."

Product: scioCD

 

Tweets

BACK_TO_TOP